Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.

Requejo C, Ruiz-Ortega JA, Cepeda H, Sharma A, Sharma HS, Ozkizilcik A, Tian R, Moessler H, Ugedo L, Lafuente JV

Molecular neurobiology1 Jan 2018Cited by 18 (Europe PMC)

PMID28840482DOI10.1007/s12035-017-0741-xPepBankPUB-28840482

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

01AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In rats with experimental Parkinson's disease, nanowired Cerebrolysin reduced motor symptoms.
In plain wordsIn rats with experimental Parkinson's disease, nanowired Cerebrolysin reduced motor symptoms.
Peptide
Cerebrolysin
Outcome
DecreaseMotor symptoms
Study
ratn: not reported in source
6-hydroxydopamine Parkinson's disease model
Outcome group
Exercise and physical function · Nervous system and cognition
Source sentences
Summary
A decrease in motor symptoms was shown by rats receiving CBL.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague-Dawley male rats receiving intrastriatally 6-hydroxydopamine after a short evolution time were segregated into CBL group (rats receiving nanowired CBL), EE group (rats housed in EE), CBL + EE group (rats housed in EE and receiving nanowired CBL), and control group (rats without additional treatment).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2884048201
02AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In rats with experimental Parkinson's disease, nanowired Cerebrolysin plus enriched environment increased wheel laps versus enriched environment alone.
In plain wordsIn rats, nanowired Cerebrolysin plus enriched environment increased wheel laps compared with enriched environment alone.
Peptide
Cerebrolysin
Outcome
IncreaseWheel laps
Study
ratn: not reported in source
6-hydroxydopamine Parkinson's disease model
Comparator
Enriched environment alone
Outcome group
Exercise and physical function · Nervous system and cognition
Source sentences
Summary
EE monitoring cages revealed that rats from CBL + EE group showed more significant number of laps in the wheel than EE group.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague-Dawley male rats receiving intrastriatally 6-hydroxydopamine after a short evolution time were segregated into CBL group (rats receiving nanowired CBL), EE group (rats housed in EE), CBL + EE group (rats housed in EE and receiving nanowired CBL), and control group (rats without additional treatment).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2884048202
03AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In rats with experimental Parkinson's disease, Cerebrolysin plus enriched environment produced the highest substantia nigra neuronal density.
In plain wordsIn rats, Cerebrolysin plus enriched environment produced the highest substantia nigra neuronal density.
Peptide
Cerebrolysin
Outcome
IncreaseSubstantia nigra neuronal density
Study
ratn: not reported in source
6-hydroxydopamine Parkinson's disease model
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
In SN, CBL + EE group also presented the highest neuronal density.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague-Dawley male rats receiving intrastriatally 6-hydroxydopamine after a short evolution time were segregated into CBL group (rats receiving nanowired CBL), EE group (rats housed in EE), CBL + EE group (rats housed in EE and receiving nanowired CBL), and control group (rats without additional treatment).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2884048203
04AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Mechanism
In rats with experimental Parkinson's disease, the Cerebrolysin plus enriched environment group had a significantly higher p-Akt/Akt ratio.
In plain wordsIn rats, the Cerebrolysin plus enriched environment group had a significantly higher p-Akt/Akt ratio.
Peptide
Cerebrolysin
Outcome
Increasep-Akt/Akt ratio
Study
ratn: not reported in source
6-hydroxydopamine Parkinson's disease model
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Moreover, p-Akt/Akt and p-ERK/ERK 1/2 ratio was significant higher and caspase-3 expression was lower in CBL + EE group.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague-Dawley male rats receiving intrastriatally 6-hydroxydopamine after a short evolution time were segregated into CBL group (rats receiving nanowired CBL), EE group (rats housed in EE), CBL + EE group (rats housed in EE and receiving nanowired CBL), and control group (rats without additional treatment).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2884048204
05AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Mechanism
In rats with experimental Parkinson's disease, the Cerebrolysin plus enriched environment group had a significantly higher p-ERK/ERK ratio.
In plain wordsIn rats, the Cerebrolysin plus enriched environment group had a significantly higher p-ERK/ERK ratio.
Peptide
Cerebrolysin
Outcome
Increasep-ERK/ERK ratio
Study
ratn: not reported in source
6-hydroxydopamine Parkinson's disease model
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Moreover, p-Akt/Akt and p-ERK/ERK 1/2 ratio was significant higher and caspase-3 expression was lower in CBL + EE group.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague-Dawley male rats receiving intrastriatally 6-hydroxydopamine after a short evolution time were segregated into CBL group (rats receiving nanowired CBL), EE group (rats housed in EE), CBL + EE group (rats housed in EE and receiving nanowired CBL), and control group (rats without additional treatment).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2884048205
06AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Mechanism
In rats with experimental Parkinson's disease, the Cerebrolysin plus enriched environment group had lower caspase-3 expression.
In plain wordsIn rats, the Cerebrolysin plus enriched environment group had lower caspase-3 expression.
Peptide
Cerebrolysin
Outcome
DecreaseCaspase-3 expression
Study
ratn: not reported in source
6-hydroxydopamine Parkinson's disease model
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Moreover, p-Akt/Akt and p-ERK/ERK 1/2 ratio was significant higher and caspase-3 expression was lower in CBL + EE group.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague-Dawley male rats receiving intrastriatally 6-hydroxydopamine after a short evolution time were segregated into CBL group (rats receiving nanowired CBL), EE group (rats housed in EE), CBL + EE group (rats housed in EE and receiving nanowired CBL), and control group (rats without additional treatment).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2884048206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.